Perspectives on shorter durations of anti-HER2 therapy in early-stage HER2-positive breast cancer: a patient survey.

M BradburyM F SavardC StoberL ClemonsM ClemonsJ HiltonG PondL VandermeerSharon F McGee

Published in: Breast cancer research and treatment (2024)

Trials to investigate who can safely and effectively be treated with shorter durations of anti-HER2 therapy are needed. This study provides important insights to patients' perspectives on shorter durations of anti-HER2 treatment, and their concerns regarding potential increased cancer risk with less treatment.

Keyphrases

early stage
positive breast cancer
newly diagnosed
end stage renal disease
ejection fraction
case report
stem cells
peritoneal dialysis
prognostic factors
replacement therapy
cross sectional
bone marrow
lymph node
climate change
locally advanced